13 patents
Utility
Inhibtors of Raf kinases
14 Nov 23
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
Filed: 3 Feb 23
Utility
Inhibitors of MEK kinase
10 Oct 23
Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
Toufike Kanouni, Robert S. Kania, Jason M. Cox
Filed: 27 Feb 23
Utility
Inhibitors of MET kinase
12 Sep 23
Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania
Filed: 14 Dec 22
Utility
Inhibtors of RAF kinases
5 Sep 23
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
Filed: 6 May 22
Utility
Inhibitors of cyclin-dependent kinases
20 Sep 22
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Lee Arnold, Stephen W. Kaldor, Eric A. Murphy
Filed: 2 May 19
Utility
Inhibitors of RAF kinases
9 Aug 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
Filed: 16 Sep 21
Utility
Inhibitors of cyclin-dependent kinases
19 Jul 22
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
Filed: 11 Nov 20
Utility
Inhibitors of RAF kinases
5 Jul 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
Filed: 11 Oct 21
Utility
Inhibitors of cyclin-dependent kinases
14 Jun 22
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
Filed: 11 Nov 20
Utility
Inhibitors of fibroblast growth factor receptor kinases
31 May 22
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
Filed: 4 Jun 21
Utility
Inhibitors of RAF kinases
24 Aug 21
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
Filed: 23 Oct 20
Utility
Inhibitors of RAF kinases
23 Feb 21
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. Kaldor, Toufike Kanouni, Lee Arnold
Filed: 30 Apr 20
Utility
Inhibitors of cyclin-dependent kinases
19 Jan 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
Filed: 28 Jun 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first